IRadimed EV/FCF
The EV/FCF (Enterprise Value to Free Cash Flow) of IRadimed (IRMD) as of Aug 1, 2026 is 71.31. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 69.47 — a change of 2.64% (higher).
Get this data via API
Financial Data API
EV/FCF
71.31
YoY
2.64%
Last updated:
EV/FCF (Enterprise Value to Free Cash Flow) of IRadimed is 2026 71.31 . EV/FCF (Enterprise Value to Free Cash Flow) of IRadimed was 2025 69.47 . It decreases by 2.64% higher compared to the previous year.
Access this data via the Eulerpool API
IRadimed Stock analysis
What does IRadimed do? IRadimed Corp is an American company specializing in the development, manufacturing, and marketing of advanced medical technology products. The company was founded in 1992 and is headquartered in Winter Springs, Florida. It was founded to meet the need for advanced and precise medical devices used in intensive care. In recent years, the company has focused on the development of components and accessory products for magnetic resonance imaging (MRI) used in radiology and oncology. IRadimed Corp is known for its innovative and technologically advanced approach to the medical technology industry. The company prioritizes research and development and collaborates closely with clinics, hospitals, and medical facilities to provide the best solutions for patient care. It has a strong distribution network that allows its products to be distributed worldwide, particularly in the United States, Europe, and Asia. The company offers a wide range of medical devices and accessory products used in radiology, oncology, and other medical fields. Its specialty lies in manufacturing components and accessories for MRI. These include MRI-compatible infusion pumps, patient monitoring devices, ventilation devices, and coil arrays designed for imaging the skull and spine, as well as breast and prostate imaging. In summary, IRadimed Corp is a leading provider of medical devices and accessories for radiology, oncology, and other specialized fields. Its focus on MRI-compatible devices and accessories, as well as its collaborative approach with medical facilities, sets it apart in the industry. The company prides itself on innovation and technological advancement, offering a wide range of products tailored to the needs of patients and medical professionals. IRadimed is one of the most popular companies on Eulerpool.
Frequently Asked Questions about IRadimed stock
EV/FCF (Enterprise Value to Free Cash Flow) of IRadimed is 71.31 in 2026.
Access this data via the Eulerpool API
Valuation — IRadimed
All Key Metrics — IRadimed
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth